FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153368844> ?p ?o ?g. }

• W2153368844 endingPage "4443" @default.
• W2153368844 startingPage "4437" @default.
• W2153368844 abstract "Abstract Purpose: To evaluate the safety and biological activity of three different doses of marimastat given for 6 months to patients with biochemically relapsed prostate cancer. Experimental Design: Patients with a biochemical relapse within 2 years of primary therapy, a prostate-specific antigen (PSA) increase of at least 50% within 6 months of study entry, and no prior systemic therapy were eligible. Patients were randomized to receive marimastat at total daily doses of 5, 20, or 40 mg for 6 months unless dose-limiting toxicity or new evidence of disease occurred. Results: Thirty-nine patients were treated. Grade 3-4 reversible musculoskeletal toxicity was the only dose-limiting toxicity. Increasing dose was associated with increased probability of experiencing dose-limiting toxicity (5.9%, 42.9% and 88.9% for the 5, 20, and 40 mg groups, respectively; P = 0.03). Accrual was discontinued early on the two higher dose levels due to toxicity. A significant decrease in PSA slope was shown in the 20 mg group when compared with the 5 mg group (0.117 and −0.0046, respectively; P = 0.03) The 40 mg group (versus the 5 mg group) showed a similar change (0.109) with a trend towards significance (P = 0.07). An increased serum matrix metalloproteinase 2 level at month 3 compared with the baseline correlated with a decrease in PSA slopes (Slope, 0.001; 95% confidence interval, 0.0002-0.0018; P = 0.02). Conclusion: These data suggest that marimastat has a biological effect and may effectively delay progression in patients with biochemical relapsed prostate cancer, as shown by the change in PSA slope; however, dose-limiting toxicity at active doses is significant. Confirmatory studies with less toxic matrix metalloproteinase inhibitors employing more conventional end points are indicated. This design is feasible and potentially efficient for screening antimetastatic agents." @default.
• W2153368844 created "2016-06-24" @default.
• W2153368844 creator A5001783218 @default.
• W2153368844 creator A5002414848 @default.
• W2153368844 creator A5003107448 @default.
• W2153368844 creator A5012074439 @default.
• W2153368844 creator A5020274632 @default.
• W2153368844 creator A5020715864 @default.
• W2153368844 creator A5040293489 @default.
• W2153368844 creator A5060234674 @default.
• W2153368844 date "2005-06-15" @default.
• W2153368844 modified "2023-10-05" @default.
• W2153368844 title "Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial" @default.
• W2153368844 cites W1969558467 @default.
• W2153368844 cites W1978960711 @default.
• W2153368844 cites W1979329236 @default.
• W2153368844 cites W1986884128 @default.
• W2153368844 cites W2011134969 @default.
• W2153368844 cites W2014735061 @default.
• W2153368844 cites W2031877879 @default.
• W2153368844 cites W2048013581 @default.
• W2153368844 cites W2051347744 @default.
• W2153368844 cites W2051595712 @default.
• W2153368844 cites W2058680827 @default.
• W2153368844 cites W2060848035 @default.
• W2153368844 cites W2065493263 @default.
• W2153368844 cites W2071879495 @default.
• W2153368844 cites W2072363606 @default.
• W2153368844 cites W2077995672 @default.
• W2153368844 cites W2094794880 @default.
• W2153368844 cites W2101112263 @default.
• W2153368844 cites W2104692426 @default.
• W2153368844 cites W2110188261 @default.
• W2153368844 cites W2114608969 @default.
• W2153368844 cites W2115864893 @default.
• W2153368844 cites W2141283971 @default.
• W2153368844 cites W2150980881 @default.
• W2153368844 cites W2157082106 @default.
• W2153368844 cites W2162651519 @default.
• W2153368844 cites W2322201873 @default.
• W2153368844 cites W3151254939 @default.
• W2153368844 cites W4245042014 @default.
• W2153368844 cites W4295773257 @default.
• W2153368844 cites W81300945 @default.
• W2153368844 doi "https://doi.org/10.1158/1078-0432.ccr-04-2252" @default.
• W2153368844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15958628" @default.
• W2153368844 hasPublicationYear "2005" @default.
• W2153368844 type Work @default.
• W2153368844 sameAs 2153368844 @default.
• W2153368844 citedByCount "54" @default.
• W2153368844 countsByYear W21533688442013 @default.
• W2153368844 countsByYear W21533688442014 @default.
• W2153368844 countsByYear W21533688442015 @default.
• W2153368844 countsByYear W21533688442016 @default.
• W2153368844 countsByYear W21533688442017 @default.
• W2153368844 countsByYear W21533688442018 @default.
• W2153368844 countsByYear W21533688442019 @default.
• W2153368844 countsByYear W21533688442020 @default.
• W2153368844 countsByYear W21533688442021 @default.
• W2153368844 countsByYear W21533688442022 @default.
• W2153368844 countsByYear W21533688442023 @default.
• W2153368844 crossrefType "journal-article" @default.
• W2153368844 hasAuthorship W2153368844A5001783218 @default.
• W2153368844 hasAuthorship W2153368844A5002414848 @default.
• W2153368844 hasAuthorship W2153368844A5003107448 @default.
• W2153368844 hasAuthorship W2153368844A5012074439 @default.
• W2153368844 hasAuthorship W2153368844A5020274632 @default.
• W2153368844 hasAuthorship W2153368844A5020715864 @default.
• W2153368844 hasAuthorship W2153368844A5040293489 @default.
• W2153368844 hasAuthorship W2153368844A5060234674 @default.
• W2153368844 hasConcept C121608353 @default.
• W2153368844 hasConcept C126322002 @default.
• W2153368844 hasConcept C126894567 @default.
• W2153368844 hasConcept C143998085 @default.
• W2153368844 hasConcept C168563851 @default.
• W2153368844 hasConcept C188816634 @default.
• W2153368844 hasConcept C2776694085 @default.
• W2153368844 hasConcept C2780192828 @default.
• W2153368844 hasConcept C29730261 @default.
• W2153368844 hasConcept C44249647 @default.
• W2153368844 hasConcept C65409693 @default.
• W2153368844 hasConcept C71924100 @default.
• W2153368844 hasConcept C90924648 @default.
• W2153368844 hasConceptScore W2153368844C121608353 @default.
• W2153368844 hasConceptScore W2153368844C126322002 @default.
• W2153368844 hasConceptScore W2153368844C126894567 @default.
• W2153368844 hasConceptScore W2153368844C143998085 @default.
• W2153368844 hasConceptScore W2153368844C168563851 @default.
• W2153368844 hasConceptScore W2153368844C188816634 @default.
• W2153368844 hasConceptScore W2153368844C2776694085 @default.
• W2153368844 hasConceptScore W2153368844C2780192828 @default.
• W2153368844 hasConceptScore W2153368844C29730261 @default.
• W2153368844 hasConceptScore W2153368844C44249647 @default.
• W2153368844 hasConceptScore W2153368844C65409693 @default.
• W2153368844 hasConceptScore W2153368844C71924100 @default.
• W2153368844 hasConceptScore W2153368844C90924648 @default.
• W2153368844 hasIssue "12" @default.
• W2153368844 hasLocation W21533688441 @default.

• next